ストックスクリーナーアプリを入手
1.33
0.76%
0.01
プレマーケット:
1.35
0.02
+1.50%
前日終値:
$1.32
開ける：
$1.34
24時間の取引高:
104.04K
Relative Volume:
0.73
時価総額：
$91.47M
収益：
-
当期純損益:
$-10.41M
株価収益率:
-3.9572
EPS:
-0.3361
ネットキャッシュフロー:
$-3.69M
1週間 パフォーマンス:
-8.28%
1か月 パフォーマンス:
+4.72%
6か月 パフォーマンス:
-4.32%
1年 パフォーマンス:
-48.25%
1日の値動き範囲:
$1.30
$1.34
1週間の範囲:
$1.30
$1.50
52週間の値動き範囲:
$1.05
$3.10
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Compare TELO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.33 | 90.78M | 0 | -10.41M | -3.69M | -0.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-21 | 開始されました | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc (TELO) 最新ニュース
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study - Sahm
GLP safety trials find Telomir 1 well tolerated, Telomir Pharmaceuticals, Inc. asserts - Traders Union
Telomir Pharmaceuticals Receives FDA Clearance for IND of Telomir-Zn in Phase 1/2 Trial for Triple-Negative Breast Cancer 8 - Minichart
Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer - marketscreener.com
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn - TipRanks
Telomir Pharmaceuticals (TELO) wins FDA IND clearance for Telomir‑Zn Phase 1/2 cancer trial - Stock Titan
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - Corsicana Daily Sun
FDA IND clearance puts Telomir's TNBC drug into first human testing - Stock Titan
Telomir shares surge after breakthrough tumor suppressor gene reactivation data - MSN
Telomir (TELO) CEO Aminov issued 7,319,710 shares in TELI acquisition - Stock Titan
Telomir Pharmaceuticals Acquires TELI, Secures Global Rights to Lead Drug Telomir-1 - citybuzz -
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition By Investing.com - Investing.com India
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals and Files Form 8-K with Nasdaq Listing - Minichart
Telomir Pharmaceuticals Completes TELI Acquisition, Expands Telomir-1 Rights - TipRanks
Telomir completes acquisition of TELI Pharmaceuticals - Investing.com
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition - Investing.com
Telomir completes acquisition of TELI Pharmaceuticals By Investing.com - Investing.com UK
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Telomir Completes Acquisition of TELI Pharmaceuticals in All-Stock Deal, Issuing 34.4M Shares - TradingView
Telomir (NASDAQ: TELO) closes TELI acquisition, issues 34,389,710 shares and adds funding - Stock Titan
Telomir locks up worldwide rights to its lead drug, with $1M now and $4M tied to milestones - Stock Titan
TELO Telomir Pharmaceuticals gains slightly even as Q4 2025 EPS lands far below analyst consensus estimates. - UBND thành phố Hải Phòng
Telomir Pharmaceuticals unveils preclinical data for Telomir-1 at AACR Annual Meeting - Traders Union
Telomir Pharmaceuticals (TELO) Stock: Is It a Compelling Buy (Tumbles Hard) 2026-04-20Analyst Consensus - Xã Vĩnh Công
Telomir Pharmaceuticals (TELO) Stock: Why You Should Hold It (+2.29%) 2026-04-15Most Discussed Stocks - UBND thành phố Hải Phòng
Is Telomir Pharmaceuticals (TELO) Stock Lagging the Market | Price at $1.25, Up 2.46%Crowd Risk Alerts - Newser
Sentiment Review: Will Telomir Pharmaceuticals Inc outperform small cap indexesPortfolio Risk Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: How does Telomir Pharmaceuticals Inc compare to its peers2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Is Telomir Pharmaceuticals (TELO) Stock Growing Now | Price at $1.30, Up 2.36%Chart Patterns - Newser
TELO SEC FilingsTelomir Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
Is Telomir Pharmaceuticals (TELO) Stock defensive in downturns | Price at $1.27, Down 3.79%Stock Analysis - Newser
Telomir Pharmaceuticals submits IND in U.S. for Telomir-1 in TNBC - BioWorld News
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) Targeting Advanced Triple-Negative Breast Cancer - Minichart
Telomir submits IND application for cancer drug candidate By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance - TipRanks
Telomir Pharmaceuticals Regains Nasdaq Compliance Following 2025 Annual Shareholders Meeting - Minichart
Telomir Pharmaceuticals Submits IND for Telomir-1 in Advanced Triple-Negative Breast Cancer - National Today
Telomir Pharmaceuticals regains Nasdaq compliance after annual meeting - Investing.com
Nasdaq confirms Telomir (NASDAQ: TELO) back in listing compliance - Stock Titan
Telomir submits IND application for cancer drug candidate - Investing.com
Telomir takes experimental TNBC therapy to FDA for metastatic disease - Stock Titan
Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC - Investing.com
Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC - TradingView
Telomir Pharmaceuticals (NASDAQ: TELO) files IND for Telomir-1 in advanced TNBC - Stock Titan
Telomir Shareholders Approve Equity Plan and Bylaw Changes - The Globe and Mail
Pullback Watch: Is Telomir Pharmaceuticals Inc stock a buy or sell2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Telomir Pharmaceuticals 2026 Annual Meeting Results: Shareholder Votes, Amended Bylaws, and Incentive Plan Approval - Minichart
Telomir Pharmaceuticals, Inc. unveils Telomir-1 for cellular dysfunction targeting iron and zinc balance - Traders Union
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Bluffton Today
Telomir Pharmaceuticals Inc (TELO) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):